The sympathetic nervous system and the metabolic syndrome.

Studies performed in the past two decades have unequivocally shown that several of the components of the metabolic syndrome are associated with indirect and direct markers of adrenergic overdrive. This is the case for hypertension and obesity, in which resting tachycardia, elevated plasma norepinephrine values, increased sympathetic nerve traffic, as well as augmented levels of total and regional norepinephrine spillover have been reported. This is also the case for insulin resistance, i.e. a metabolic condition frequently complicating the various components of the pathological condition identified as the 'metabolic syndrome'. After briefly describing the epidemiological and the cardiovascular risk profile of the disease, this paper will examine the behaviour of the sympathetic nervous system in the metabolic syndrome as well as the mechanisms potentially responsible for this neurogenic abnormality. This will be followed by an analysis of the role played by neuroadrenergic factors in disease progression as well as in the pathogenesis of its complications. Finally, the therapeutic implications of these findings will be highlighted.

[1]  I. Wittmann Insulin Resistance and Metabolic Syndrome , 2007, EJIFCC.

[2]  G. Mancia,et al.  Metabolic Syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study: Daily Life Blood Pressure, Cardiac Damage, and Prognosis , 2007, Hypertension.

[3]  Elisabeth Lambert,et al.  Mechanisms of sympathetic activation in obesity-related hypertension. , 2006, Hypertension.

[4]  Francesco Locatelli,et al.  Renal manifestations in the metabolic syndrome. , 2006, Journal of the American Society of Nephrology : JASN.

[5]  S. Haffner,et al.  Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program-Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects. , 2006, Diabetes care.

[6]  M. Muggeo,et al.  Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. , 2006, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[7]  Ian Janssen,et al.  The importance of waist circumference in the definition of metabolic syndrome: prospective analyses of mortality in men. , 2006, Diabetes care.

[8]  Y. Nakaya,et al.  Relationships between thermic effect of food, insulin resistance and autonomic nervous activity. , 2006, The journal of medical investigation : JMI.

[9]  A. Karter,et al.  Prediction of Type 2 Diabetes Mellitus With Alternative Definitions of the Metabolic Syndrome: The Insulin Resistance Atherosclerosis Study , 2005, Circulation.

[10]  R. D'Agostino,et al.  Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus , 2005, Circulation.

[11]  P. Nestel,et al.  Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[12]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[13]  Yuichiro Oka,et al.  Metabolic syndrome and carotid atherosclerosis: role of elevated blood pressure. , 2005, Journal of atherosclerosis and thrombosis.

[14]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[15]  Kathryn Bean,et al.  Cardiovascular Mortality in Overweight Subjects: The Key Role of Associated Risk Factors , 2005, Hypertension.

[16]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[17]  J. Oppert,et al.  Metabolic syndrome in relation to structure and function of large arteries: a predominant effect of blood pressure. A report from the SU.VI.MAX. Vascular Study. , 2005, American journal of hypertension.

[18]  G. Mancia,et al.  Obstructive Sleep Apnea–Dependent and –Independent Adrenergic Activation in Obesity , 2005, Hypertension.

[19]  K. Mather,et al.  Obesity, Insulin Resistance, and the Metabolic Syndrome: Determinants of Endothelial Dysfunction in Whites and Blacks , 2005, Circulation.

[20]  G. Mancia,et al.  Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome , 2005, Diabetologia.

[21]  S. Srinivasan,et al.  Influence of metabolic syndrome on arterial stiffness and its age-related change in young adults: the Bogalusa Heart Study. , 2005, Atherosclerosis.

[22]  M. Tarnopolsky,et al.  Regulating adiponectin: of flax and flux , 2005, Diabetologia.

[23]  K. Petersen,et al.  Mechanisms of insulin resistance in humans and possible links with inflammation. , 2005, Hypertension.

[24]  G. Leoncini,et al.  Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients , 2005, Journal of internal medicine.

[25]  F. Magrini,et al.  Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: The Evaluation of Target Organ Damage in Hypertension study , 2005, Journal of hypertension.

[26]  N. Shostak,et al.  Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome , 2005, Current medical research and opinion.

[27]  N. Wong,et al.  Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. , 2005, Diabetes care.

[28]  R. Bergman,et al.  Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. , 2005, American journal of physiology. Endocrinology and metabolism.

[29]  A. F. Mackintosh,et al.  Sympathetic Neural Activation in Nondiabetic Metabolic Syndrome and Its Further Augmentation by Hypertension , 2004, Hypertension.

[30]  G. Mancia,et al.  Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives , 2004, Journal of hypertension.

[31]  G. Doronzo,et al.  Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance , 2004, European journal of clinical investigation.

[32]  F. Magrini,et al.  Metabolic syndrome and target organ damage in untreated essential hypertensives , 2004, Journal of hypertension.

[33]  Nathan D. Wong,et al.  Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults , 2004, Circulation.

[34]  G. Grassi Counteracting the sympathetic nervous system in essential hypertension , 2004, Current opinion in nephrology and hypertension.

[35]  Hong Tang,et al.  Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. , 2004, Diabetes research and clinical practice.

[36]  T. Ogihara,et al.  Hypoadiponectinemia Is an Independent Risk Factor for Hypertension , 2004, Hypertension.

[37]  G. Grassi Leptin, sympathetic nervous system, and baroreflex function , 2004, Current hypertension reports.

[38]  P. Calverley,et al.  Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. , 2004, European heart journal.

[39]  Ralph B D'Agostino,et al.  Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands , 2004, BMJ : British Medical Journal.

[40]  Sung Hee Choi,et al.  Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic diseases. , 2004, The American journal of clinical nutrition.

[41]  Jing Chen,et al.  The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults , 2004, Annals of Internal Medicine.

[42]  E. Scott,et al.  Impact of Type 2 Diabetes Mellitus on Sympathetic Neural Mechanisms in Hypertension , 2003, Circulation.

[43]  Robert Wolk,et al.  Obesity, Sleep Apnea, and Hypertension , 2003, Hypertension.

[44]  E. Kraegen,et al.  Insulin action, regional fat, and myocyte lipid: altered relationships with increased adiposity. , 2003, Obesity research.

[45]  M. Carnethon,et al.  Association between microalbuminuria and the metabolic syndrome: NHANES III. , 2003, American journal of hypertension.

[46]  S. Haffner,et al.  The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. , 2003, Diabetes care.

[47]  G. Mancia,et al.  Effects of Heart Rate Changes on Arterial Distensibility in Humans , 2003, Hypertension.

[48]  G. Mancia,et al.  European guidelines on cardiovascular disease prevention in clinical practice; Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) , 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[49]  P. Macfarlane,et al.  Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study , 2003, Circulation.

[50]  A. Zanchetti,et al.  Is there a relationship between left ventricular mass and plasma glucose and lipids independent of body mass index? Results of the Gubbio Study. , 2003, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[51]  S. Priori,et al.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. , 2003, Journal of hypertension.

[52]  Reubin Andres,et al.  Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. , 2003, Journal of the American College of Cardiology.

[53]  Arya M. Sharma,et al.  Association between adiponectin and mediators of inflammation in obese women. , 2003, Diabetes.

[54]  S. Lewington Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .

[55]  Shankuan Zhu,et al.  The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Archives of internal medicine.

[56]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[57]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[58]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[59]  G. Mancia,et al.  Short- and Long-Term Neuroadrenergic Effects of Moderate Dietary Sodium Restriction in Essential Hypertension , 2002, Circulation.

[60]  G. Mancia,et al.  Arterial distensibility in humans. Modulating mechanisms, alterations in diseases and effects of treatment. , 2002, Journal of hypertension.

[61]  H. Snieder,et al.  Insulin Resistance Syndrome and Left Ventricular Mass in Healthy Young People , 2002, The American journal of the medical sciences.

[62]  H. Koyama,et al.  Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[63]  R. Bergman,et al.  Extreme insulin resistance of the central adipose depot in vivo. , 2002, Diabetes.

[64]  A. Mark,et al.  Selective Resistance to Central Neural Administration of Leptin in Agouti Obese Mice , 2002, Hypertension.

[65]  G. Mancia,et al.  Participation of the Hypothalamus-Hypophysis Axis in the Sympathetic Activation of Human Obesity , 2001, Hypertension.

[66]  Daniel Levy,et al.  Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study , 2001, The Lancet.

[67]  J. Reid Update on rilmenidine: clinical benefits. , 2001, American journal of hypertension.

[68]  G. Grassi Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. , 2001, Journal of hypertension.

[69]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[70]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[71]  L. Landsberg Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why) , 2001, Journal of hypertension.

[72]  T. Pischon,et al.  Hypothesis: β-Adrenergic Receptor Blockers and Weight Gain , 2001 .

[73]  R. Bergman,et al.  Free Fatty Acids and Pathogenesis of Type 2 Diabetes Mellitus , 2000, Trends in Endocrinology & Metabolism.

[74]  B. Trimarco,et al.  Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double‐blind parallel study versus amlodipine , 2000, Journal of hypertension.

[75]  G. Mancia,et al.  Adrenergic and Reflex Abnormalities in Obesity-Related Hypertension , 2000, Hypertension.

[76]  S. O'Sullivan,et al.  The effects of exercise and training on human cardiovascular reflex control. , 2000, Journal of the autonomic nervous system.

[77]  S. Klaus,et al.  Resting metabolic rate and substrate use in obesity hypertension. , 2000, Hypertension.

[78]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[79]  M. Laakso,et al.  Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[80]  G. Grassi,et al.  Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. , 1999, Hypertension.

[81]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[82]  D. Seals,et al.  Neural mechanisms in human obesity-related hypertension. , 1999, Journal of hypertension.

[83]  N. Mikhail,et al.  Obesity and hypertension. , 1999, Progress in cardiovascular diseases.

[84]  G. Grassi,et al.  How to assess sympathetic activity in humans. , 1999, Journal of hypertension.

[85]  V. Somers,et al.  Human obesity is characterized by a selective potentiation of central chemoreflex sensitivity. , 1999, Hypertension.

[86]  A. Dyer,et al.  Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in Industry. , 1999, American journal of epidemiology.

[87]  G Mancia,et al.  Heart rate as marker of sympathetic activity , 1998, Journal of hypertension.

[88]  V. Somers,et al.  Sympathetic activity in obese subjects with and without obstructive sleep apnea. , 1998, Circulation.

[89]  G. Mancia,et al.  Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. , 1998, Circulation.

[90]  C. Sartori,et al.  Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. , 1997, Circulation.

[91]  G. Jennings,et al.  Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. , 1997, Circulation.

[92]  M. Böhm,et al.  The Cardiac β-Adrenoceptor–Mediated Signaling Pathway and Its Alterations in Hypertensive Heart Disease , 1997 .

[93]  G. Dagenais,et al.  Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. , 1997, Circulation.

[94]  K. Petersen,et al.  Mechanism of free fatty acid-induced insulin resistance in humans. , 1996, The Journal of clinical investigation.

[95]  B. Duncan,et al.  A Metabolic Syndrome in Whites and African-Americans: The Atherosclerosis Risk in Communities baseline study , 1996, Diabetes Care.

[96]  G. Reaven,et al.  Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. , 1996, The New England journal of medicine.

[97]  G. Mancia,et al.  Sympathetic modulation of radial artery compliance in congestive heart failure. , 1995, Hypertension.

[98]  G. Mancia,et al.  Sympathetic activation in obese normotensive subjects. , 1995, Hypertension.

[99]  F. Sannajust,et al.  Involvement of imidazoline-preferring receptors in regulation of sympathetic tone. , 1994, The American journal of cardiology.

[100]  S. Julius,et al.  Sympathetics, insulin resistance and coronary risk in hypertension: the 'chicken-and-egg' question. , 1994, Journal of hypertension.

[101]  G. Mancia,et al.  Physical training and baroreceptor control of sympathetic nerve activity in humans. , 1994, Hypertension.

[102]  E. Ravussin,et al.  Reduced sympathetic nervous activity. A potential mechanism predisposing to body weight gain. , 1993, The Journal of clinical investigation.

[103]  P. Vollenweider,et al.  Suppression of Insulin‐Induced Sympathetic Activation and Vasodilation by Dexamethasone in Humans , 1993, Circulation.

[104]  L. Mandarino,et al.  Interaction between glucose and free fatty acid metabolism in human skeletal muscle. , 1993, The Journal of clinical investigation.

[105]  B. Trimarco,et al.  Insulin reduces reflex forearm sympathetic vasoconstriction in healthy humans. , 1993, Hypertension.

[106]  S. Julius,et al.  Reflex sympathetic activation induces acute insulin resistance in the human forearm. , 1993, Hypertension.

[107]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[108]  A. Rantala,et al.  Multiple metabolic syndrome: aspects of genetic epidemiology and molecular genetics. , 1992, Annals of medicine.

[109]  L. Landsberg Obesity and hypertension: experimental data. , 1992, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[110]  J. K. Dunn,et al.  Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[111]  A. Mark,et al.  Insulin Increases Sympathetic Activity but Not Blood Pressure in Borderline Hypertensive Humans , 1992, Hypertension.

[112]  Egan Bm Neurohumoral, hemodynamic and microvascular changes as mechanisms of insulin resistance in hypertension: a provocative but partial picture. , 1991 .

[113]  G. Jennings,et al.  Biochemical evidence of sympathetic hyperactivity in human hypertension. , 1991, Hypertension.

[114]  N. Schork,et al.  Hyperkinetic borderline hypertension in Tecumseh, Michigan , 1991, Journal of hypertension.

[115]  M. Laakso,et al.  Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. , 1990, The Journal of clinical investigation.

[116]  E A Anderson,et al.  Elevated Sympathetic Nerve Activity in Borderline Hypertensive Humans Evidence From Direct Intraneural Recordings , 1989, Hypertension.

[117]  N. Kaplan The Deadly Quartet: Upper-Body Obesity, Glucose Intolerance, Hypertriglyceridemia, and Hypertension , 1989 .

[118]  G. Reaven Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.

[119]  G. Reaven Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[120]  L. Landsberg,et al.  Insulin and hypertension: lessons from obesity. , 1987, The New England journal of medicine.

[121]  Y. Yamori,et al.  Humoral trophic influence on cardiovascular structural changes in hypertension. , 1984, Hypertension.

[122]  S. Schanberg,et al.  Hypertension and cardiovascular hypertrophy during chronic catecholamine infusion in rats. , 1983, Life sciences.

[123]  E. Rasio Passage of glucose through the cell membrane of capillary endothelium. , 1975, American Journal of Physiology.

[124]  M. Wellner,et al.  Adipose tissue and circulating endothelial cell specific molecule-1 in human obesity. , 2006, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[125]  G. Mancia,et al.  New-onset diabetes and antihypertensive drugs. , 2006, Journal of Hypertension.

[126]  J. Oppert,et al.  Metabolic Syndrome in Relation to Structure and Function of Large Arteries: A Predominant Effect of Blood Pressure , 2005 .

[127]  H. Hashimoto,et al.  Hypertension Is the Most Common Component of Metabolic Syndrome and the Greatest Contributor to Carotid Arteriosclerosis in Apparently Healthy Japanese Individuals , 2005, Hypertension Research.

[128]  B. Howard,et al.  Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). , 2004, The American journal of cardiology.

[129]  G. Mancia,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003, European heart journal.

[130]  M. Stolar,et al.  Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. , 2003, Clinical therapeutics.

[131]  A. Zanchetti,et al.  European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension , 2003 .

[132]  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2002, Circulation.

[133]  T. Pischon,et al.  Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. , 2001, Hypertension.

[134]  A. Dyer,et al.  Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality. , 1999 .

[135]  S. Nesbitt,et al.  Tachycardia: an important determinant of coronary risk in hypertension. , 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[136]  G Mancia,et al.  Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. , 1998, Hypertension.

[137]  T. Ogihara,et al.  Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. , 1997, American journal of hypertension.

[138]  M. Castellano,et al.  The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. , 1997, Hypertension.

[139]  B. Wallin,et al.  Increased norepinephrine spillover into the jugular veins in essential hypertension. , 1992, Hypertension.

[140]  B. Egan Neurohumoral, hemodynamic and microvascular changes as mechanisms of insulin resistance in hypertension: a provocative but partial picture. , 1991, International journal of obesity.

[141]  G. Jennings,et al.  Regional norepinephrine turnover in human hypertension. , 1989, Clinical and experimental hypertension. Part A, Theory and practice.

[142]  N. Kaplan The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. , 1989, Archives of internal medicine.

[143]  I. G. Joshua,et al.  Distributions of microvascular pressure in skeletal muscle of one-kidney, one clip, two-kidney, one clip, and deoxycorticosterone-salt hypertensive rats. , 1984, Hypertension.